XBI - SPDR S&P Biotech ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
88.92
+1.03 (+1.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close87.89
Open88.12
Bid0.00 x 0
Ask0.00 x 0
Day's Range87.73 - 89.02
52 Week Range61.14 - 90.33
Volume2,645,725
Avg. Volume4,346,263
Net Assets4.17B
NAV84.83
PE Ratio (TTM)N/A
Yield0.24%
YTD Return43.77%
Beta (3y)1.70
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • Barrons.com3 days ago

    Overriding the Windfall? Why Boring Is in Biotech's Earnings Future

    Biotech stocks face a challenging 2018. Large companies are feeling pressed to do growth-spurring deals while the rally in smaller firms has pushed up their prices. And then there are the management teams ...

  • How Is Bioverativ’s Alprolix Positioned Now?
    Market Realist11 days ago

    How Is Bioverativ’s Alprolix Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.

  • How Ionis’s Spinraza Performed in 3Q17
    Market Realist11 days ago

    How Ionis’s Spinraza Performed in 3Q17

    What's the Word on Ionis Pharmaceuticals This January?

  • Analysts’ Recommendations for Incyte in January 2018
    Market Realist12 days ago

    Analysts’ Recommendations for Incyte in January 2018

    As we discussed earlier, Incyte (INCY) reported a 41.6% rise in its revenue to $381.5 million in 3Q17. Further, Wall Street analysts expect a 26.7% rise in Incyte’s revenue to $413.8 million in 4Q17 and a 35.9% rise in its revenue to $1.5 billion for the entirety of 2017. Incyte’s stock price has fallen nearly 4.3% over the last 12 months and nearly 3.9% year-to-date in 2018.

  • Analyst Recommendations for Ignyta and Its Peers in January 2018
    Market Realist13 days ago

    Analyst Recommendations for Ignyta and Its Peers in January 2018

    Delaware-based Ignyta (RXDX) is focused on precision medicine in oncology. It endeavors to eradicate residual disease or the source of a reoccurrence of cancer in targeted patient populations. Ignyta is pursuing an integrated therapeutic and diagnostic strategy to treat cancer patients.

  • 3 Sector ETFs for 2018
    Zacks13 days ago

    3 Sector ETFs for 2018

    Inside three sector ETFs that could prove to be good picks for this year.

  • One big biotech stock looks poised for a breakout in 2018, technician says
    CNBC19 days ago

    One big biotech stock looks poised for a breakout in 2018, technician says

    This year could prove to be another big year for biotech stocks after an impressive run in 2017.

  • Barrons.com25 days ago

    Shipwreck? Biotech's Lightweight CEOs Add to 2018 Challenges

    U.S. drug approvals are rolling in at about twice last year’s pace, leaving investors with mixed feelings. In 2018, the approach of midterm elections could keep drug prices in the spotlight. Add another challenge for large U.S. biotechs: Their median CEO tenure has plunged from 11 years in 2007 to just one year in 2017, according to a study by investment bank Leerink.

  • Top Sector ETFs of 2017
    Zackslast month

    Top Sector ETFs of 2017

    Winning sector ETFs of 2017.

  • Barrons.comlast month

    Cell, Not Sell: Be in Biotech in 2018

    It's been a tale of two biotechs this year, with large cap stocks largely trailing their smaller peers, and the iShares Nasdaq Biotechnology ETF (IBB) trailing the  SPDR S&P Biotech ETF (XBI), which, as an equal-weighted fund, is skewed toward smaller companies.  Some analysts see the pain for large cap biotechs continuing, and Jefferies' Michael Yee and his team believe that while biotech in general is a good place to invest next year, the bigger names could have a bit of a tougher go of things--although they could still make headway. In addition, we believe the market will be favorable for biotech and tax repatriation is one tailwind that could stimulate a more positive view as large-caps are likely to react well to M&A and SMID-cap is likely to benefit on a more positive Street view towards M&A (hence win-win for large and small biotech).

  • Barrons.comlast month

    Biotech: No Happy New Year?

    Biotech has had an interesting year, write Leerink's Geoffrey Porges and Bradley Canino. The first half of the year saw the market cheering the Food and Drug Administration's faster pace of approvals, successful new products, and the receding threat of price controls. Then in the last third of the year, sales growth slowed, due to reimbursement restrictions and competitive pricing.

  • Barrons.comlast month

    Biotech: Lean in on the Pullback

    Investors have cooled on biotechnology stocks, taking some money off the table after enjoying a greater than 25% gain year-to-date through the end of September. Biotech mutual funds and exchange-traded ...

  • Barrons.comlast month

    For the Love of Biotech, Know What You Own

    Don't judge an exchange-traded fund by its cover -- obvious advice, but apparently not obvious enough. The SPDR S&P Biotech ETF (XBI) has returned 42% so far this year, more than double that of the iShares ...

  • How Biotechs, Drugmakers Would Fare Under The Senate's Tax Bill
    Investor's Business Daily2 months ago

    How Biotechs, Drugmakers Would Fare Under The Senate's Tax Bill

    Biotech and pharma stocks dipped after the Senate's GOP tax reform leaves the fate of a key tax credit up in the air.

  • Barrons.com2 months ago

    Biotech: You Really, Really Don't Like Me

    Biotechnology fund outflows persist. For the week ended Nov. 29, biotechnology mutual funds and exchange-traded funds saw outflows of some $329 million, according to Lipper/AMG Data Services, which tracks ...

  • Barrons.com2 months ago

    Biotech: What You Don't Know…And What You Don't Know You Don't Know…Could Hurt You

    It can be tricky putting a price tag on a biotech company, especially one that offers no profits but promises of big success one day in the future. Just because someone wearing a lab coat makes a breakthrough, doesn’t necessarily mean a blockbuster drug is on the horizon. Years can pass before it’s clear whether an experimental treatment will generate returns for a drug maker.

  • Barrons.com2 months ago

    Easy Come, Easy Go: Biotech's Fading Flows

    Investors appear to be hitting the snooze button on biotechnology stocks. Net flows are slowing after seeing two consecutive weeks of fresh money. Biotech fund flows, including mutual funds and exchange-traded funds, were essentially flat for the week ended Nov. 15.

  • Biotechs Sell Off In Droves — Are Investors Seeking Mergers?
    Investor's Business Daily2 months ago

    Biotechs Sell Off In Droves — Are Investors Seeking Mergers?

    Loxo's deal with Bayer had a bigger impact on the biotech sector than you'd expect, an industry observer said.

  • Barrons.com2 months ago

    Biotech: Go With the Flow

    Fresh money marched into biotechnology stock mutual funds and exchange-traded funds for the week ended Nov. 8,  the second consecutive week of net inflows in the past six weeks, according to Lipper/AMG data. About $62 million flowed into 100 funds with some $58.7 billion in assets collectively. Flows are critical to biotech stock strength, according to Raymond James analyst Laura Chico. "In our view, biotech strength will likely be driven in part by specialist funds," she said in note published Thursday.

  • The two big bullish catalysts for biotech stocks
    CNBC3 months ago

    The two big bullish catalysts for biotech stocks

    The XBI biotech ETF has surged 49 percent in 2017 to its highest level in more than two years. Some say the move isn't over just yet.